Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.47 |
| ▸ | KCNJ6 | P48051 | 10/20 | 0.42 |
| ▸ | KCNJ5 | P48544 | 10/20 | 0.42 |
| ▸ | KCNJ3 | P48549 | 10/20 | 0.42 |
| ▸ | ABL1 | P00519 | 4/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030579 | 0.98 | ORAI1 (0.47) | ORAI1KCNJ6KCNJ5KCNJ3ABL1 | |
| SCHEMBL27903542 | 0.90 | ORAI1 (0.44) | ORAI1KCNJ6KCNJ5KCNJ3ABL1 | |
| SCHEMBL2028880 | 0.82 | ABL1 (0.62) | ABL1AXLIRAK4SRCMAPK14 | |
| SCHEMBL2025593 | 0.82 | ABL1 (0.47) | KCNJ6KCNJ5KCNJ3ABL1AXL | |
| SCHEMBL2025978 | 0.82 | ABL1 (0.51) | ORAI1KCNJ6KCNJ5KCNJ3ABL1 | |
| SCHEMBL2028690 | 0.82 | ABL1 (0.49) | ABL1AXLIRAK4SRCMAPK14 | |
| SCHEMBL3184425 | 0.82 | KCNJ6 (0.57) | KCNJ6KCNJ5KCNJ3IRAK4MAPK14 | |
| SCHEMBL3176505 | 0.81 | KCNJ6 (0.56) | KCNJ6KCNJ5KCNJ3IRAK4MAPK14 | |
| SCHEMBL3185420 | 0.78 | KCNJ6 (0.56) | KCNJ6KCNJ5KCNJ3IRAK4 | |
| SCHEMBL27903551 | 0.74 | ABL1 (0.44) | ABL1AXLIRAK4SRCMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2073811-B1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8586565-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| WO-2013036232-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| US-7790756-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | ABL1, MCL1, ABL2 | ORAI1 4716/4885KCNJ6 4625/4885KCNJ5 4519/4885 |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | MYLK3, MYLK, CDK3 | ORAI1 4032/4885KCNJ6 699/4885KCNJ5 651/4885 |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | MYLK3, MYLK, CDK3 | ORAI1 4032/4885KCNJ6 699/4885KCNJ5 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.